Wellington Management Group LLP Buys 195,042 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

Wellington Management Group LLP boosted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 197.2% during the 2nd quarter, Holdings Channel reports. The firm owned 293,925 shares of the biotechnology company’s stock after buying an additional 195,042 shares during the quarter. Wellington Management Group LLP’s holdings in BioCryst Pharmaceuticals were worth $2,939,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Larson Financial Group LLC grew its position in shares of BioCryst Pharmaceuticals by 1,188.0% during the fourth quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 3,267 shares in the last quarter. Allworth Financial LP bought a new position in BioCryst Pharmaceuticals during the second quarter valued at approximately $52,000. Focus Partners Wealth bought a new position in BioCryst Pharmaceuticals during the third quarter valued at approximately $77,000. Envestnet Portfolio Solutions Inc. purchased a new position in BioCryst Pharmaceuticals during the 4th quarter valued at approximately $81,000. Finally, Mercer Global Advisors Inc. ADV purchased a new position in BioCryst Pharmaceuticals during the 3rd quarter valued at approximately $81,000. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Performance

NASDAQ:BCRX opened at $8.29 on Friday. The firm has a market capitalization of $2.12 billion, a PE ratio of -5.53 and a beta of 0.57. The stock’s fifty day moving average is $9.69 and its 200 day moving average is $9.23. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $6.00 and a fifty-two week high of $11.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The company had revenue of $218.25 million during the quarter, compared to analyst estimates of $183.28 million. During the same period in the previous year, the firm earned $0.15 earnings per share. BioCryst Pharmaceuticals’s quarterly revenue was up 33.6% compared to the same quarter last year. Equities analysts forecast that BioCryst Pharmaceuticals, Inc. will post -2.25 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, June 30th. Wedbush cut their target price on shares of BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Cantor Fitzgerald boosted their price target on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 30th. JPMorgan Chase & Co. began coverage on shares of BioCryst Pharmaceuticals in a research note on Monday, July 13th. They set a “neutral” rating and a $12.00 price target on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and set a $16.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday. Seven investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $20.40.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.